Incidence and predictive score for delayed hemolytic transfusion reaction in adult patients with sickle cell disease

American Journal of Hematology

Volumn 92, Issue 12, 2017, Pages 1340-1348

  Narbey, David ^a,b,c   Habibi, Anoosha ^b,c,d   Chadebech, Philippe ^a,b,c   Mekontso Dessap, Armand ^b,d,e   Khellaf, Mehdi ^d,e   Lelièvre, Jean Daniel ^d,e   Godeau, Bertrand ^d   Michel, Marc ^d,e   Galactéros, Frédéric ^b,c,d,e   Djoudi, Rachid ^a   Bartolucci, Pablo ^b,c,d,e   Pirenne, France ^a,b,c,e  

^a ETABLISSEMENT FRANÇAIS DU SANG   (France)

^b INSERM U955   (France)

^c Laboratory of Excellence GR Ex   (France)

^d HENRI MONDOR HOSPITAL   (France)

^e FACULTÉ DE MÉDECINE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIBODY;

ADULT; ANTIBODY PRODUCTION; ARTICLE; BLOOD TRANSFUSION; BLOOD TRANSFUSION REACTION; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MORTALITY; OBSERVATIONAL STUDY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; SICKLE CELL ANEMIA; COMPLICATION; HEMOLYSIS; MIDDLE AGED; PATHOLOGY; RISK ASSESSMENT; UTILIZATION; YOUNG ADULT;

ADULT; ANEMIA, SICKLE CELL; BLOOD TRANSFUSION; FEMALE; HEMOLYSIS; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RISK ASSESSMENT; TRANSFUSION REACTION; YOUNG ADULT;

EID: 85033222882     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.24908     Document Type: Article

References (46)

1. Adams RJ, McKie VC, Hsu L, et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. N Engl J Med. 1998;339:5–11.
2. Vidler JB, Gardner K, Amenyah K, Mijovic A, Thein SL. Delayed haemolytic transfusion reaction in adults with sickle cell disease: a 5-year experience. Br J Haematol. 2015;169:746–753.
3. Vichinsky EP, Earles A, Johnson RA, Hoag MS, Williams A, Lubin B. Allo-immunization in sickle cell anemia and transfusion of racially unmatched blood. N Engl J Med. 1990;322:1617–1621.
4. Aygun B, Padmanabhan S, Paley C, Chandrasekaran V. Clinical significance of RBC alloantibodies and autoantibodies in sickle cell patients who received transfusions. Transfusion. 2002;42:37–43.
5. Venkateswaran L, Teruya J, Bustillos C, Mahoney D, Jr, Mueller BU. Red cell exchange does not appear to increase the rate of allo- and auto-immunization in chronically transfused children with sickle cell disease. Pediatr Blood Cancer. 2011;57(2):294–296.
6. Silvy M, Tournamille C, Babinet J, et al. Red blood cell immunization in sickle cell disease: evidence of a large responder group and a low rate of anti-Rh linked to partial Rh phenotype. Haematologica. 2014;99(7):115–177.
7. Meunier N, Rodet M, Bonin P, et al. Study of 206 transfused sickle cell disease patients: immunization, transfusion safety and red blood cell supply. Transfus Clin Biol. 2008;15:377–382.
8. de Montalembert M, Dumont MD, Heilbronner C, et al. Delayed hemolytic transfusion reaction in children with sickle cell disease. Haematologica. 2011;96(6):801–807.
9. Chou ST, Jackson T, Vege S, Smith-Whitley K, Friedman DF, Westhoff CM. High prevalence of red blood cell alloimmunization in sickle cell disease despite transfusion from Rh-matched minority donors. Blood. 2013;122:1062–1071.
10. Fasano RM, Booth GS, Miles M, et al. Red blood cell alloimmunization is influenced by recipient inflammatory state at time of transfusion in patients with sickle cell disease. Br J Haematol. 2015;168(2):291–300.
11. King KE, Shirey RS, Lankiewicz MW, Young-Ramsaran J, Ness PM. Delayed hemolytic transfusion reactions in sickle cell disease: simultaneous destruction of recipients’ red cells. Transfusion. 1997;37:376–381.
12. Win N, New H, Lee E, de la Fuente J. Hyperhemolysis syndrome in sickle cell disease: case report (recurrent episode) and literature review. Transfusion. 2008;48:1231–1238.
13. Chadebech P, Habibi A, Nzouakou R, et al. Delayed hemolytic transfusion reaction in sickle cell disease patients: evidence of an emerging syndrome with suicidal red blood cell death. Transfusion. 2009;49:1785–1792.
14. Danaee A, Inusa B, Howard J, Robinson S. Hyperhemolysis in patients with hemoglobinopathies: a single-center experience and review of the literature. Transfus Med Rev. 2015;29(4):220–230.
15. Gardner K, Hoppe C, Mijovic A, Thein SL. How we treat delayed haemolytic transfusion reactions in patients with sickle cell disease. Br J Haematol. 2015;170(6):745–756.
16. Habibi A, Mekontso-Dessap A, Guillaud C, et al. Delayed hemolytic transfusion reaction in adult sickle cell disease: presentations, outcomes, and treatments of 99 referral center episodes. Am J Hematol. 2016;91(10):989–994.
17. Dumas G, Habibi A, Onimus T, et al. Eculizumab salvage therapy for delayed hemolysis transfusion reaction in sickle cell disease patients. Blood. 2016;127(8):1062–1064.
18. Adisa OA, Hu Y, Ghosh S, Aryee D, Osunkwo I, Ofori-Acquah SF. Association between plasma free haem and incidence of vaso-occlusive episodes and acute chest syndrome in children with sickle cell disease. Br J Haematol. 2013;162(5):702–705.
19. Diamond WJ, Brown FL, Bitterman P, Klein HG, Davey RJ, Winslow RM. Delayed hemolytic transfusion reaction presenting as sickle-cell crisis. Ann Intern Med. 1980;93:231–233.
20. Talano JA, Hillery CA, Gottschall JL, Baylerian DM, Scott JP. Delayed hemolytic transfusion reaction/hyperhemolysis syndrome in children with sickle cell disease. Pediatrics. 2003;111:661–665.
21. Michot JM, Driss F, Guitton C, et al. Immunohematologic tolerance of chronic transfusion exchanges with erythrocytapheresis in sickle cell disease. Tranfusion. 2015;55:357–363.
22. Mekontso Dessap A, Pirenne F, Razazi K, et al. A diagnostic nomogram for delayed hemolytic transfusion reaction in sickle cell disease. Am J Hematol. 2016;91(12):1181–1184.
23. Sins JW, Biemond BJ, van den Bersselaar SM, et al. Early occurrence of red blood cell alloimmunization in patients with sickle cell disease. Am J Hematol. 2016;91(8):763–769.
24. Meinderts SM, Sins JWR, Fijnvandraat CJ, et al. Non-classical FCGR2C polymorphism associates with protection from red blood cell allo-immunization in sickle cell disease. Blood. 2017, doi:10.1182/blood-2017-05-784876.
25. Vandenbroucke JP, Pearce N. Incidence rates in dynamic populations. Int J Epidemiol. 2012;41(5):1472–1479.
26. Doll R, Hill AB. Lung cancer and other causes of death in relation to smoking. A second report on the mortality of British doctors. BMJ. 1956;ii:1071–1081.
27. El-Masri MM. Cumulative incidence and incidence rate. Can Nurse. 2012;108(8):14.
28. Concato J, Feinstein AR, Holford TR. The risk of determining risk with multivariable models. Ann Intern Med. 1993;118:201–210.
29. El Sanharawi M, Naudet F. Comprendre la régression logistique. J Fr Ophtalmol. 2013;36(8):710–715. doi:10.1016/j.jfo.2013.05.008. Epub 2013 Aug 14.
30. Giraudeau B, Ravaud PH. Évaluation des règles de décision clinique. Revue D'Épidémiologie Et De Santé Publique. 2000;48:561–569.
31. Wasson JH, Sox HC, Neff RK, Goldman L. Clinical prediction rules. Applications and methodological standards. N Engl J Med. 1985;313:793–799.
32. Wyatt JC, Altman DG. Commentary: prognostic models: clinically useful or quickly forgotten? Br Med J. 1995;311:1539–1541.
33. Laporte S. Comment élabore-t-on un score clinique, un score de risque? JRDIA. 2014;39(2):94.
34. Wicki J, Perneger TV, Junod A, Bounameaux H, Perrier A. Assessing clinical probability of pulmonary embolism in the emergency ward. Arch Intern Med. 2001;161:92–97.
35. Rouleau DM, Place A, Bérubé M, Laflamme YG, Feldman D. Rehabilitation after lower limb injury: development of a predictive score (RALLI score). Can J Surg. 2015;58(3):278–283.
36. Wang HQ, Yang J, Yang JY, Wang WT, Yan LN. Development and validation of a predictive score for perioperative transfusion in patients with hepatocellular carcinoma undergoing liver resection. Hepatobiliary Pancreat Dis Int. 2015;14(4):394–400.
37. Jerraya H, Bousslema A, Frikha F, Dziri C. Is there a place for the Glasgow-Blatchford score in the management of upper gastrointestinal bleeding? Tunis Med. 2011;89(12):916–919.
38. Lambert J, Lipkovich I. A Macro For Getting More Out Of Your ROC Curve. SAS Global Forum 2008.
39. Harrell FE, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996;15(4):361–387.
40. Van Houwelingen JC, Le Cessie S. Predictive value of statistical models. Stat Med. 1990;9(11):1303–1325.
41. Miller ME, Hui SL, Tierney WM. Validation techniques for logistic regression models. Stat Med. 1991;10(8):1213–1226.
42. Coutant C, Olivier C, Lambaudie E, et al. Comparison of models to predict nonsentinel lymph node status in breast cancer patients with metastatic sentinel lymph nodes: a prospective multicenter study. J Clin Oncol. 2009;27:2800–2808.
43. Jacobson RH. Validation des épreuves sérologiques pour le diagnostic des maladies infectieuses. Rev Sci Tech Off Int Epiz. 1998;17(2):487–506.
44. Zalpuri S, Zwaginga JJ, Le Cessie S, Elshuis J, Schonewille H, van der Bom JG. Red-blood-cell alloimmunization and number of red-blood-cell transfusions. Vox Sang. 2012;102(2):144–149.
45. Noizat-Pirenne F, Habibi A, Mekontso-Dessap A, et al. The use of rituximab to prevent severe delayed haemolytic transfusion reaction in immunized patients with sickle cell disease. Vox Sang. 2015;108:262–267.
46. Nickel RS, Hendrickson JE, Fasano RM, et al. Impact of red blood cell alloimmunization on sickle cell disease mortality: a case series. Transfusion. 2016;56(1):107–114.